Stem cell therapy delivery: treading the regulatory tightrope.

Area of Science:

• Regenerative Medicine
• Ophthalmology
• Biotechnology

Background:

• Stem cell therapy holds promise for various diseases, including Parkinson's, diabetes, and cancer.
• Limbal epithelial stem cell therapy for ocular surface disease is a clinically successful application.
• Academic research-driven stem cell therapies face significant regulatory challenges.

Purpose of the Study:

• To present a model for delivering accredited limbal epithelial stem cell therapy.
• To address key regulatory questions for academic stem cell therapies.
• To guide clinician-scientists in navigating regulatory approval processes.

Main Methods:

• Developing a model for 'accredited' therapy delivery.
• Ensuring compliance with Good Manufacturing Practice (GMP) and EU Tissues and Cells Directive.
• Addressing critical regulatory aspects: donor consent, raw materials, quality assurance, lab specifications, indemnity, and funding.

Main Results:

• A framework for regulatory compliance in academic stem cell therapy delivery has been established.
• Key regulatory considerations for research-driven stem cell therapies are identified.
• The model facilitates the transition of innovative therapies from research to clinical practice.

Conclusions:

• Navigating regulatory approval is a major challenge for stem cell therapies.
• Adherence to GMP and relevant directives is crucial for clinical translation.
• This model provides a pathway for academic researchers to overcome regulatory hurdles and deliver novel stem cell treatments.